Conditions: Chronic Gastrointestinal Graft vs Host Disease
Keywords: BDP orBec GVHD beclomethasone dipropionate bone marrow transplant hematopoietic cell transplant HCT stem cell transplant marrow transplant SCT beclomethasone 17,21-dipropionate
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 2
Healthy volunteers: no

Brief summary:
Use of an oral topically-active glucocorticoid with limited side effects may control the gastrointestinal inflammatory process of GVHD and minimize glucocorticoid exposure.

Detailed description:

Arms:
arm 1: Control arm 2: Investigational drug

Interventions: intervention 1: orBec intervention 2: Placebo
Intervention descriptions: intervention 1: None intervention 2: None

Protocol document: